AMRN - Amarin Corporation plc
| Previous Close | 3.18 |
| Open | 3.15 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 2.98 - 3.21 |
| 52 Week Range | 2.82 - 4.60 |
| Volume | 4,336,651 |
| Avg. Volume | 2,286,164 |
| Market Cap | 972.16M |
| Beta | 1.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.25 |
| Earnings Date | May 4, 2017 - May 8, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.60 |
- CNBC Videos•last month
Cramer's lightning round: I screwed up on Apache and won'...
Jim Cramer zooms through his take on callers' favorite stocks, including a mea culpa on one oil play.
- GlobeNewswire•7 days ago
New Research: Key Drivers of Growth for Amarin, Korea Electric Power, Star Bulk Carriers, 1-800 FLOWERS.COM, Clementia Pharmaceuticals, and Bank of Nova Scotia — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, April 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•7 days ago
Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions
BEDMINSTER, N.J. and DUBLIN, Ireland, April 12, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- Zacks•8 days ago
Moving Average Crossover Alert: Amarin (AMRN)
Amarin Corporation plc (AMRN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
- GlobeNewswire•8 days ago
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides
BEDMINSTER, N.J. and DUBLIN, Ireland, April 12, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- ACCESSWIRE•14 days ago
Wired News – Amarin’s REDUCE-IT Study Reached 100% Mark for Estimated Onset of Targeted Primary MACE
Stock Monitor: Pernix Therapeutics Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free research report on Amarin Corp. PLC (NASDAQ: ...
- Motley Fool•15 days ago
Boom-or-Bust News Is On Tap Soon for Amarin
Amarin has needle-moving news that's fast-approaching.
- GlobeNewswire•16 days ago
Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives
BEDMINSTER, N.J. and DUBLIN, Ireland, April 04, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- GlobeNewswire•16 days ago
Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events
BEDMINSTER, N.J., and DUBLIN, Ireland, April 04, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- Zacks•18 days ago
Implied Volatility Surging for Amarin (AMRN) Stock Options
Surging implied volatility makes Amarin (AMRN) stock lucrative to the option traders.
- Investopedia•18 days ago
7 Stocks for the Biotech Takeover Wave
Biotech M&A activity took a bit of a breather in 2017, but expect a new wave of deals in 2018.
- Thomson Reuters StreetEvents•20 days ago
Edited Transcript of AMRN earnings conference call or presentation 27-Feb-18 12:30pm GMT
Q4 2017 Amarin Corporation PLC Earnings Call
- GlobeNewswire•22 days ago
Amarin Sponsors Two Scientific Presentations Scheduled for National Kidney Foundation 2018 Spring Clinical Meetings
BEDMINSTER, N.J. and DUBLIN, Ireland, March 29, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- GlobeNewswire•22 days ago
Amarin to Present at the H.C. Wainwright Annual Global Life Sciences Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, March 28, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- GlobeNewswire•23 days ago
Amarin Commemorates National Triglycerides Day on March 28
BEDMINSTER, N.J. and DUBLIN, Ireland, March 27, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- GlobeNewswire•last month
Amarin Announces First Middle East Approval for Vascepa®
BEDMINSTER, N.J. and DUBLIN, Ireland, March 21, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- Motley Fool•last month
3 Stocks That Could Put Alibaba's Returns to Shame
Alibaba may make the headlines, but here are three other stocks that are equally strong investment opportunities.
- GlobeNewswire•last month
New Research Coverage Highlights Amarin, Corbus Pharmaceuticals, Green Brick Partners, Immutep, Texas Capital Bancshares, and G1 THERAPEUTICS — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, March 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•last month
Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs
BEDMINSTER, N.J. and DUBLIN, Ireland, March 12, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- GlobeNewswire•last month
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein (hsCRP)
BEDMINSTER, N.J. and DUBLIN, Ireland, March 12, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- CNBC•last month
Cramer's lightning round: I screwed up on Apache and won't stop you from selling
Jim Cramer zooms through his take on callers' favorite stocks, including a mea culpa on one oil play.
- GlobeNewswire•last month
Amarin Announces Closing of Underwriter’s Purchase of Additional Shares
BEDMINSTER, N.J., and DUBLIN, Ireland, March 05, 2018-- Amarin Corporation plc today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares, ...
- Zacks•2 months ago
Implied Volatility Surging for Amarin (AMRN) Stock Options
Surging implied volatility makes Amarin (AMRN) Stock lucrative to the option traders.
- GlobeNewswire•2 months ago
Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study
BEDMINSTER, N.J. and DUBLIN, Ireland, March 01, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- GlobeNewswire•2 months ago
Amarin Sponsors Multiple Scientific Presentations Scheduled for 2018 American College of Cardiology Annual Scientific Session & Expo
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 28, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
